Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

Christiansen, Ailsa J; Lobo, João; Fankhauser, Christian Daniel; Rothermundt, Christian; Cathomas, Richard; Batavia, Aashil A; Grogg, Josias B; Templeton, Arnoud J; Hirschi-Blickenstorfer, Anita; Lorch, Anja; Gillessen, Silke; Moch, Holger; Beyer, Jörg; Hermanns, Thomas

doi:10.3389/fonc.2022.1056823

Citations

Citation copied

Christiansen, A. J., Lobo, J., Fankhauser, C. D., Rothermundt, C., Cathomas, R., Batavia, A. A., Grogg, J. B., Templeton, A. J., Hirschi-Blickenstorfer, A., Lorch, A., Gillessen, S., Moch, H., Beyer, J., & Hermanns, T. (2022). Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. Frontiers in Oncology, 12, 1056823. https://doi.org/10.3389/fonc.2022.1056823

Abstract

INTRODUCTION

Current evidence shows that serum miR-371a-3p can identify disease recurrence in testicular germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing evidence showing the advantages of including miR-371a-3p testing to complement and overcome the classical serum tumour markers limitations, the successful introduction of a serum miRNA based test into clinical practice has been impeded by a lack of consensus regarding optimal methodologies and lack of a universal protocol and thresholds. Herein, w